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Abstract
Background: In the Asia-Pacific region many countries have adopted the WHO’s public health approach to HIV care and
treatment. We performed exploratory analyses of the factors associated with first major modification to first-line
combination antiretroviral therapy (ART) in resource-rich and resource-limited countries in the region.
Methods: We selected treatment naive HIV-positive adults from the Australian HIV Observational Database (AHOD) and the
TREAT Asia HIV Observational Database (TAHOD). We dichotomised each country’s per capita income into high/upper-
middle (T-H) and lower-middle/low (T-L). Survival methods stratified by income were used to explore time to first major
modification of first-line ART and associated factors. We defined a treatment modification as either initiation of a new class
of antiretroviral (ARV) or a substitution of two or more ARV agents from within the same ARV class.
Results: A total of 4250 patients had 961 major modifications to first-line ART in the first five years of therapy. The
cumulative incidence (95% CI) of treatment modification was 0.48 (0.44–0.52), 0.33 (0.30–0.36) and 0.21 (0.18–0.23) for
AHOD, T-H and T-L respectively. We found no strong associations between typical patient characteristic factors and rates of
treatment modification. In AHOD, relative to sites that monitor twice-yearly (both CD4 and HIV RNA-VL), quarterly
monitoring corresponded with a doubling of the rate of treatment modifications. In T-H, relative to sites that monitor once-
yearly (both CD4 and HIV RNA-VL), monitoring twice-yearly corresponded to a 1.8 factor increase in treatment
modifications. In T-L, no sites on average monitored both CD4 & HIV RNA-VL concurrently once-yearly. We found no
differences in rates of modifications for once- or twice-yearly CD4 count monitoring.
Conclusions: Low-income countries tended to have lower rates of major modifications made to first-line ART compared to
higher-income countries. In higher-income countries, an increased rate of RNA-VL monitoring was associated with increased
modifications to first-line ART.
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Introduction
The introduction of combination antiretroviral therapy (ART)
has dramatically changed the management of HIV infection.
Combination ART can suppress plasma HIV replication to levels
below the level of detection of highly sensitive contemporary
assays, allowing reconstitution of the immune system and
concomitant protection against AIDS diseases and mortality
[1,2]. Since the introduction of zidovudine (AZT) in 1987, ART
has evolved rapidly over time with multiple agents now licensed
for use [3,4]. In high-income countries where access to ART is
widely available, an effective regimen usually consists of a
combination of antiretrovirals selected from five classes, where
each class targets independent viral replication processes. The
availability of five classes of ART gives prescribers a variety of
potential initial as well as second- and third-line treatment options
that afford full virological suppression [5]. In high-income
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countries, initial ART regimens are individualized in order to
minimise toxicity and adverse events, and maximise tolerability
and efficacy of treatment. This is done to facilitate the chance of
good adherence and thereby successful long-term HIV treatment
outcomes.
In low- and middle-income countries the availability of ART is
generally more restricted, limiting prescription to a narrower
selection of ART combinations. Monitoring of disease, including
HIV RNA viral load monitoring, is also restricted in many of these
settings as is the widespread availability of expert medical care. In
response, the World Health Organization (WHO) has recom-
mended that access to HIV care including ART in such settings be
facilitated by a public health based approach. This approach
provides access to simple, affordable and well-studied ART
regimens and disease monitoring schedules that allow for adequate
care in the absence of sophisticated and expensive medical
technologies [6].
The Asia-Pacific region has a large burden of HIV with
estimates of around 4.9 million persons living with HIV/AIDS [7].
Over 85% of this burden is carried by India, China, Thailand,
Indonesia and Vietnam [7]. The scale-up of ART in the Asia-
Pacific region has increased substantially over recent years with
most countries within the region now having widespread access to
first-line ART, but only minimal second-line therapy options [8].
Most countries within the region have adopted a public health
approach-based treatment strategy aligned with the WHO
recommendations [6]. However, in this politically and econom-
ically diverse region, a number of approaches to the management
of HIV exist. Different strategies have been adopted according to a
range of considerations including HIV monitoring, ART dosing,
and were formed partly on lack of evidence as to best practice [9].
In the absence of a cure, ART is considered to be a life-long
means of achieving virological control. Numerous studies have
shown that ART prolongs and improves the quality of life of a
person living with HIV. In some settings, survival of people living
with HIV may be similar to that observed in HIV-negative
populations [10–12]. Poor adherence to the appropriate ART
dosing schedule selects for drug resistance and can shorten the
regimens durability [13]. Because of the critical importance of
achieving and maintaining virological control, prescribers in
collaboration with their patients may adapt and change ART
regimens if individuals are experiencing barriers to adequate
adherence. This decision to modify treatment is an important
consideration as there are currently only a finite number of active
ART combinations available for life-long treatment [14].
There are minimal data published on the rates of switching or
modifying first-line ART for any reason in the Asia-Pacific region.
The objective of this analysis was to explore the differences
between resource rich and resource limited countries rates of
major modifications made to first-line ART. Specifically we seek to
further describe by income group, the first ART regimens
initiated, frequency of HIV disease monitoring, and factors
associated with major modifications to first-line ART regimens.
Methodology
Data Collection
The Asia-Pacific HIV Observational Database (APHOD)
consists of two adult and one pediatric cohort and is part of the
International Epidemiological Database Evaluating AIDS (IeDEA)
collaboration. This analysis utilises data from the two adult cohorts
in the Asia-Pacific region; the Australian HIV Observational
Database (AHOD) and the TREAT Asia HIV Observational
Database (TAHOD). APHOD data are collected twice annually
(March & September) on a core set of demographic and clinical
variables including information to assess and monitor patterns of
ART, treatment efficacy, patterns of toxicity, markers of disease
stage, and to monitor HIV-related and non-HIV-related causes of
death. Data collection methodology for each cohort and baseline
clinical characteristics have been described elsewhere [15,16].
Data are transferred electronically to The Kirby Institute, Sydney
and all data are subjected to internal quality control and assurance
procedures. This analysis is based on all data collated as of 31
March 2011 for AHOD and 30 September 2011 for TAHOD.
Ethics and study governance approval for AHOD was granted
by the University of New South Wales Human Research Ethics
Committee, and site-specific study governance granted by their
nominated institutional review boards. Patient’s written and
informed consent was obtained at time of enrolment. Ethics
approval was granted for TAHOD by the University of New
South Wales Human Research Ethics Committee. Sites specific
study governance was granted by site-relevant institutional review
boards. Written informed consent was not sought in TAHOD
unless required by a site’s local institutional review board.
Informed consent was waived at some sites as information is
collected via an anonymous case report form. All study procedures
were developed in accordance with the revised 1975 Helsinki
Declaration.
We included all patients with a known starting date of
combination ART who had not previously received mono/duo
ART (treatment naive). We defined initial ART as two nucleos(-
t)ide reverse transcriptase inhibitor (N(t)RTI) anchored with one of
the following; non-nucleoside reverse transcriptase inhibitor
(NNRTI), protease inhibitor (PI), or integrase inhibitor (II). To
reduce the reliance on treatment records captured prior to patient
enrolment and to ensure our analysis was based largely on
treatment records captured after enrolment, we further restricted
our analysis population to patients who initiated ART after or
#two years prior to cohort enrolment. We excluded patients who
reported an undetectable plasma HIV RNA viral load (RNA-VL)
measurement (defined as ,400 copies/ml) prior to the reported
ART initiation date.
Statistical Analysis
For comparative purposes we classified countries participating
in TAHOD into a dichotomous income variable based on the
World Bank’s per capita 2009 gross national income (GNI)
estimates [17]. We defined high- to upper middle-income as per
capita GNI.$3945 and lower middle- to low-income as per capita
GNI,$3946. We summarised typical patient characteristics by
income grouping and evaluated the frequency of HIV disease
monitoring.
The primary endpoint for this analysis was time until first major
first-line treatment modification, defined as either initiating a new
class of antiretroviral or a substitution of two or more of the
original antiretroviral agents with different agents from within the
same ART class. Patients were censored at five years of follow-up
after initiating ART. We defined a patient as lost to follow-up if
they had not presented to care for at least one year prior to the last
site’s data transfer date. Patients who died were considered to have
completed follow-up and were censored at their date of death. We
recorded the primary reason for ART modification as identified by
the treating nurse or physician. Reasons for modifying an ART
regimen were aggregated into four broad categories- treatment
failure (clinical, immunological, virological), adverse event or
toxicity, patient or physician decision (including drug-drug
interaction switches) and unknown/not reported.
Modifications to First-Line ART in APHOD
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Table 2. Patient demographics by country income grouping.
AHOD TAHOD TAHOD
(n = 945) High Income Low Income
(n = 1260) (n = 2045)
Sex N (%) N (%) N (%)
Male 891 (94) 951 (75) 1434 (70)
Female 54 (4) 309 (25) 611 (30)
Age at ART initiation (Years)
less than 30 121 (13) 273 (22) 590 (29)
30 to 50 646 (68) 829 (66) 1313 (64)
greater than 50 178 (19) 158 (13) 142 (7)
mean 41.1 38.1 35.1
median (interquartile range) 40.3 (33.4–47.5) 36.2 (30.9–43.4) 33.8 (29.1–39.5)
AIDS
None 793 (84) 511 (41) 709 (35)
Yes 152 (16) 749 (59) 1336 (65)
AIDS illness pre-ART 50 (33) 173 (23) 343 (26)
AIDS illness post-ART 102 (67) 576 (77) 993 (74)
Exposure
Homosexual 644 (68) 392 (31) 151 (7)
Heterosexual 120 (13) 736 (58) 1345 (66)
IDU 50 (5) 34 (3) 319 (16)
Other 131 (14) 98 (8) 230 (11)
HBV
Negative 721 (76) 884 (70) 1202 (59)
Positive 36 (4) 175 (14) 134 (7)
Not Tested 188 (20) 201 (16) 709 (35)
HCV
Negative 737 (78) 887 (70) 769 (38)
Positive 80 (8) 78 (6) 384 (19)
Not Tested 128 (14) 295 (23) 892 (44)
CD4 cell count at ART initiation*
mean (cells/mL) 305 150 128
median (interquartile range) 271 (159–400) 125 (34–227) 110 (38–199)
Log RNA at ART initiation*
mean (copies/ml) 4.85 4.7 4.96
median (interquartile range) 4.96 (4.44–5.35) 4.73 (4.15–5.30) 5.0 (4.56–5.57)
Year ART Initiation
1996 to 2004 499 (53) 728 (58) 507 (25)
2005 to 2011 446 (47) 532 (42) 1538 (75)
Time followed on ART
mean (years) 5.3 5.1 3.1
median (interquartile range) 3.8 (1.8–8.8) 5.5 (2.9–7.5) 2.4 (0.9–5.1)
CD4 measurements (per year per person)
mean 3.4 1.9 1.7
median (interquartile range) 3 (2–4) 2 (1–2) 1 (1–2)
RNA measurements (per year per person)
Mean 3.3 1.4 0.6
median (interquartile range) 3 (2–4) 1 (1–2) 0 (0–1)
*Closest record to ART initiation within a window of 6 month prior to ART and 1 week following ART initiation.
doi:10.1371/journal.pone.0064902.t002
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We tabulated by income grouping (AHOD, TAHOD-High,
TAHOD-Low) the number of individual antiretroviral agents used
at ART initiation, class of anchor agent used in the first-line ART
regimen, reported reason for ART modification, and ART
regimen switched-to. We used competing risk methods (as
described by Fine and Gray [18]) to estimate the cumulative
incidence of patients that made a major modification to their first-
line ART regimen. We used multivariable Cox proportional
hazards methods to evaluate any association between patient
characteristics and rates of major modification to ART. Factors
evaluated included sex, age at ART initiation, HIV exposure
category (men who have sex with men, injecting drug user,
heterosexual contact and other), hepatitis B virus (HBV) and
hepatitis C virus (HCV) seropositivity, year of ART initiation
(1996–2004 or 2005–2011), pre-ART AIDS-defining illness, pre-
ART CD4 count (0–199, 200–349, 350–500, .500 cells/mL or
unknown), pre-ART HIV RNA-VL (1–104, 104–106, .106
copies/ml and unknown) and an indicator for site resourcing
(see below). Multivariable models were run separately on subsets of
data split by income grouping. For comparative purposes we
applied the same a priori defined covariate models and used the
same reference level for each categorical factor across each model.
Each country within its respective income grouping has different
levels of resources allocated to manage HIV. Furthermore, within
each country, individual treating sites can have differing capacities
to provide HIV care and treatment (e.g. urban vs rural). To
evaluate associations between site resourcing and rates of major
modifications to ART, we used a proxy indicator variable for site
resourcing. We defined site resourcing as a function of the average
proportion of patients having ‘‘x’’ yearly, routine HIV monitoring
laboratory measurements (RNA-VL and CD4 cell counts). To
assign this indicator we first calculated for each site the proportion
of patients that had on average in a year- one, two, three or four
CD4 cell counts measured along with zero, one, two, three or four
RNA-VL measurements. Using a median cutoff, we assigned for
each site the highest number of measurements for which the
average proportion of patients was greater than 50%. For
example, if a site on average had 78% of its patients having three
or more CD4 cell count measurement per year, but only 45% for
four or more CD4 cell count measurements per year, then it would
be assigned an average of three CD4 cell count measurements per
year. Similarly, for RNA-VL, if the same site on average had 89%
of its patients having two RNA-VL measurement per year, but
only 36% for three RNA-VL measurements per year, then it
would be assigned an average of two RNA-VL measurements per
year. The two monitoring schedules were then concatenated to
form the resourcing variable – i.e. 3CD4::2RNA-VL. Using a 50%
cutoff point for the classification of site resourcing has the
interpretation- more than half of the patients at the site had 3 or more CD4
cell counts measurements and 2 or more HIV RNA-VL measurements per year.
It was not a requirement that CD4 cell counts and RNA-VL had
to be measured on the same date.
Results
Of the 3378 AHOD patients enrolled by 31 March 2011, 945
(28%) satisfied the analysis eligibility criteria. Of the AHOD
patients excluded from the analysis, 2111 (62%) were not included
due to timing of ART initiation (ART initiation date .2 years
prior to enrolment) and 158 (5%) were excluded as they received
mono/duo therapy prior to first-line ART. Similarly for TAHOD,
of the 5988 TAHOD patients enrolled by 30 September 2011,
3305 (55%) satisfied the analysis eligibility criteria. Of the
TAHOD patients excluded from the analysis, 2444 (41%) were
not included due to the timing of ART initiation and 115 (2%)
were excluded for prior mono/duo therapy exposure. The mean
time followed on ART for AHOD and TAHOD-High was five
years compared to approximately three years for TAHOD-Low.
Similar rates (95% confidence intervals) of patients lost to follow
up are reported for AHOD: 4.9 (4.3–5.6) per 100 patient years
and TAHOD-High: 4.6 (4.1–5.1) per 100 patient-years. TAHOD-
Figure 1. Time to first major modification of ART (any reason) by country income grouping. Cumulative Incidence are adjusted for
competing risk of death (solid line) with mean 95% confidence bands. Sensitivity analysis (dashed line) adjusts for competing risk of death or lost to
follow-up.
doi:10.1371/journal.pone.0064902.g001
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Low had a slightly higher rate, 7 (6.4–7.7) per 100 patient-years.
The crude mortality rate for AHOD was 0.82 (0.61–1.12) per 100
patient years, for TAHOD-High: 0.92 (0.71–1.19) per 100 patient
years and for TAHOD-Low: 1.64 (1.34–2.00) per 100 patient
years.
The estimated rate of a major modification in AHOD was 14.7
(13.3–16.4) per 100 person-years (Table 1). The highest major
modification rate for TAHOD-High was in Singapore, 15.7 (11.3–
21.8) per 100 person-years and the lowest in Hong Kong, 5.7 (3.5–
9.2) per 100 person-years. Similarly for TAHOD-Low, the highest
rate was in India, 6.7 (5.5–8.1) per 100 person-years and lowest in
Vietnam, 3.3 (2.0–5.5) per 100 person-years. The average patient
age at ART initiation in AHOD was 41 years compared to 38
years for TAHOD-High and 35 years old for TAHOD-Low
(Table 2). AHOD HIV exposure is predominately through
homosexual contact as opposed to TAHOD in which the majority
reported transmission is through heterosexual contact. The
proportion of HIV exposure through injecting drug use (IDU)
was highest in TAHOD-Low (16%) vs. TAHOD-High (3%) or
AHOD (5%). There were differences for HBV surface antigen
positivity across AHOD (5%) and TAHOD (7–14%). TAHOD-
High/Low reported more AIDS-defining illnesses, 59–65% of
patients, compared to AHOD- 16%. Of those AIDS-defining
illnesses, timing of the event, pre-ART or post-ART, were similar.
Mean pre-ART CD4 cell count was approximately 2-fold higher
in AHOD compared to TAHOD-High/Low (300 vs. 150 cells/
mL). Pre-ART RNA-VL was similar across the income groups.
The proportion of patients initiating ART in more recent periods,
2005–2011, was highest in TAHOD-Low (75%) compared to
AHOD (43%) and TAHOD-High (42%). The estimated median
(q1–q3 quartiles) number of CD4 cell measurements per year per
patient are AHOD: 3 (2–4), TAHOD-High: 2 (1–2), TAHOD-
Low: 1 (1–2). The estimated median number of RNA-VL
measurements were as follows: AHOD: 3 (2–4), TAHOD-High:
2 (1–2), TAHOD-Low: 0 (0–1).
Table 3 presents by income group the distribution of anchor
agent used in first-line ART initiated and the regimen switch-to
following modification. The proportions of reasons given for
Table 3. Antiretroviral agents available for first-line ART, ART anchor agent, reported reason for major modification and selected
switched-to ART regimen by country income grouping.
AHOD TAHOD TAHOD
N (%) High Income Low Income
N (%) N (%)
Number of different ARV agents used for initial ART regimen*
N(t)RTI 9 7 7
NNRTI 2 2 2
PI 8 9 5
II 1 1 0
Initial ART regimen
2 N(t)RTI+NNRTI 574 (61) 852 (68) 1976 (97)
2 N(t)RTI+PI 279 (30) 364 (29) 67 (3)
2 N(t)RTI+II 25 (3) 6 (0) 0 (0)
Other (non-standard, e.g. 3 N(t)RTI) 67 (7) 38 (3) ,5 (0)
Number of switches from initial ART regimen 350 352 259
Reported reason for modification
Treatment failure 47 (19) 45 (13) 73 (29)
Adverse event/toxicity 97 (38) 141 (41) 107 (42)
Patient decision/Physician decision 110 (43) 162 (47) 76 (30)
Not reported 96 ,5 ,5
Modified ART regimen
Initial ART: 2 N(t)RTI+NNRTI
2 N(t)RTI+NNRTI 48 (30) 67 (34) 85 (35)
2 N(t)RTI+PI 75 (47) 69 (35) 66 (27)
2 N(t)RTI+II 6 (4) 0 (0) 0 (0)
Other (non-standard) 29 (18) 63 (32) 93 (38)
Initial ART: 2 N(t)RTI+PI
2 N(t)RTI+PI 42 (27) 80 (65) ,5 (10)
2 N(t)RTI+NNRTI 64 (41) 30 (24) 9 (65)
2 N(t)RTI+II 9 (6) ,5 (5) 0 (0)
Other (non-standard) 41 (26) 8 (6) ,5 (25)
*Individual ARV agents with each class where less than 5 people initiated where excluded from the total count.
N(t)RTI = Nucleos(t)ide Reverse Transcriptase Inhibitor, NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor, PI = Protease Inhibitors, II = Integrase Inhibitor.
doi:10.1371/journal.pone.0064902.t003
Modifications to First-Line ART in APHOD
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e64902
Figure 2. Time to first major modification of ART by country income grouping stratified by reported reason for modification. Panel
(a) - reported treatment failure, Panel - (b) adverse event/toxicity, Panel (c) - patient/physician decision. Cumulative Incidence are adjusted for
competing risk of death and competing reasons for modification. Shaded bands are mean 95% confidence bands.
doi:10.1371/journal.pone.0064902.g002
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treatment modification by income group are also presented in
Table 3. The rate of major modification made to first-line ART by
income group adjusted for competing risk of death (dashed line -
competing risk of death and lost to follow-up) are presented, along
with an at-risk population table in Figure 1. After five years of
ART, adjusting for the competing risk of death, the cumulative
incidence (95% CI) of first-line treatment modifications was 0.48
(0.44–0.52) for AHOD, 0.33 (0.30–0.36) for TAHOD-High and
0.21 (0.18–0.23) for TAHOD-Low.
The cumulative incidence for treatment modification adjusted
for competing risk of death and competing reason for modification
are presented in Figure 2. Table 4 outlines clinical factors and
associations of rates of major modifications to first-line ART by
income grouping. Multivariable estimated hazard ratios by income
grouping were similar in relative magnitude and direction for most
covariates. The majority of covariates including sex, age at ART
initiation, HIV exposure, HBV serostatus, pre-ART AIDS-
defining Illness, pre-ART CD4 and pre-ART RNA-VL, were
not significantly associated with major treatment modifications.
HCV positive serostatus and more recent periods of ART
initiation were indicative of reduced rates of treatment modifica-
tion across all income grouping models.
Figure 3 plots multivariable model estimate hazard ratios for the
site resourcing covariate by income group (adjusted for factors
listed above). In AHOD, the relative base was two CD4 counts
and two RNA-VLs per year (e.g. monitored twice-yearly). In
Table 4. Predictors of major first-line modification by income grouping.
AHOD TAHOD-High TAHOD-Low
Hazard Ratio p Hazard Ratio p Hazard Ratio p
Sex
Male 1.00 1.00 1.00
Female 0.92 (0.55–1.55) 0.75 0.93 (0.7–1.25) 0.64 0.76 (0.56–1.03) 0.08
Age at ART initiation (years)
,30 1.00 1.00 1.00
30–50 1.07 (0.76–1.49) 0.71 0.79 (0.61–1.03) 0.08 1.04 (0.77–1.4) 0.81
.50 1.14 (0.76–1.71) 0.52 0.87 (0.6–1.25) 0.45 0.81 (0.46–1.44) 0.47
Exposure
Homosexual 1.00 1.00 1.00
Heterosexual 0.92 (0.63–1.34) 0.67 1.34 (0.97–1.86) 0.08 1.17 (0.69–1.98) 0.56
IDU 1.29 (0.81–2.07) 0.28 1.57 (0.81–3.05) 0.18 1.16 (0.58–2.33) 0.67
Other 0.93 (0.67–1.27) 0.63 1.08 (0.66–1.75) 0.77 0.98 (0.52–1.86) 0.96
Hepatitis B
Neg/Not Tested 1.00 1.00 1.00
Positive 1.05 (0.59–1.84) 0.88 1.21 (0.88–1.66) 0.24 1.14 (0.68–1.9) 0.62
Hepatitis C
Neg/Not Tested 1.00 1.00 1.00
Positive 0.63 (0.4–0.97) 0.04 0.87 (0.53–1.41) 0.56 0.65 (0.39–1.11) 0.12
Year of ART Initiation
1996–2004 1.00 1.00 1.00
2005–2011 0.81 (0.64–1.02) 0.08 0.7 (0.54–0.91) 0.01 0.62 (0.48–0.81) ,0.001
No 1.00 1.00 1.00
Yes 1.43 (1.02–2.01) 0.04 0.97 (0.77–1.21) 0.77 1.15 (0.88–1.5) 0.32
CD4 cell count at ART initiation (cells/mL)*
0–199 1.00 1.00 1.00
200–350 1 (0.75–1.35) 0.99 1.28 (0.92–1.76) 0.14 1.19 (0.86–1.64) 0.29
350–500 1.1 (0.78–1.55) 0.60 1.45 (0.93–2.25) 0.10 0.61 (0.19–1.93) 0.40
.500 0.99 (0.68–1.45) 0.97 1.86 (1–3.45) 0.05 1.77 (0.72–4.36) 0.21
Unknown 1.12 (0.63–2.01) 0.69 1.1 (0.79–1.54) 0.58 1.24 (0.83–1.85) 0.29
RNA–VL at ART initiation (copies/ml)*
1–104 1.00 1.00 1.00
104–106 0.76 (0.52–1.11) 0.15 0.71 (0.44–1.17) 0.18 1.59 (0.54–4.72) 0.40
.106 0.81 (0.55–1.17) 0.26 0.78 (0.49–1.25) 0.31 2.24 (0.8–6.27) 0.13
Unknown 0.79 (0.43–1.44) 0.44 1.01 (0.62–1.64) 0.96 1.46 (0.54–3.99) 0.46
Hazard ratios calculated from multivariable model including adjustment for site resourcing.
*Closest record to ART initiation within a window of 6 month prior to ART and 1 week following ART initiation.
doi:10.1371/journal.pone.0064902.t004
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AHOD, sites that monitored on average four-times per year
corresponded with an 2-fold increase in the rate of major first-line
modification. Similarly for TAHOD-High, relative to once-yearly
monitoring (both CD4 counts and RNA-VL), sites that monitor
twice-yearly demonstrated an increase in rate of first-line
modifications by a factor of 1.8. No sites in TAHOD-Low
monitored one-yearly CD4 count and RNA-VL concurrently.
There were no differences in modifications to first-line ART for
patients who had one or two CD4 count measurements per year.
Discussion
In the Asia-Pacific region, the overall rate of major modification
to first-line ART was associated with country income and HIV
monitoring levels, particularly RNA-VL. Low- to lower middle-
income countries typically had lower rates of major modification
to first-line ART by a factor of 0.36 (0.31–0.41) relative to
Australia. We found little evidence of significant associations
between treatment modification and standard patient character-
istics. By evaluating rates of major modifications and associations
with a proxy indicator for site resourcing, we showed that there is a
relationship between the number of RNA-VL tests and major
modification to first-line ART. In AHOD, relative to sites that
monitor twice-yearly, quarterly monitoring corresponded with an
approximate doubling of the rate of major modification. We saw a
similar pattern in TAHOD-High, where relative to sites that
monitored once-yearly, a doubling of monitoring to twice-yearly
corresponded to just below a doubling of major modifications. We
were unable to evaluate this association in TAHOD-Low as no
sites performed at least once-yearly concurrent monitoring of CD4
count and RNA-VL. Within the lower income sites, an increase of
CD4 monitoring from once- to twice-yearly monitoring did not
result in an increase in major modification made to first-line ART.
Given that one goal of HIV monitoring is to provide guidance
on the optimal time to switch ART, it is unsurprising that
increasing the frequency of RNA-VL monitoring also increases the
rate of major modifications made to first-line ART. We speculate
that regular and frequent point-of-care visits lead to continual
dialogue and discussion of patient experiences and concerns about
their wellbeing including review and discussion of all test results.
Modification of ART may also be on the basis of reporting of
adverse events, barriers to adherence, observed toxicity on routine
test results (e.g. reduced estimated glomerular filtration rate,
subclinical but biochemical hepatitis, anemia, etc.) leading to more
treatment modifications aimed at maximising benefit and mini-
mising adverse events. Figure 2 collectively outlines this point. The
rate of treatment modification due to treatment failure is relatively
low and similar across all income groups. However the rate of
treatment modification reported due to adverse events/toxicity (or
patient/physician decisions) is much higher in higher income
countries compared to lower income countries. It is unlikely that
the ART regimens distributed in lower income countries are less
toxic or better tolerated than their higher income counterparts.
Therefore we believe this data indicates that higher income
countries have additional flexibility to make treatment modifica-
tions on varying levels of reported adverse events/toxicity or by
choice of the patient or at the discretion of the treating physician.
It still remains unclear if access to all available ARVs and
quarterly RNA-VL monitoring actually increases or decreases the
number of unnecessary treatment modifications. An analysis by
the EuroSIDA group found that the risk of virological failure
following one year of well-tolerated fully suppressive ART is low
[19]. Patients in that analysis were monitored quarterly and the
authors concluded that twice-yearly monitoring could be an
effective monitoring schedule for stable patients. To date there are
few randomised clinical trial or cohort data evaluating the optimal
timing of HIV disease monitoring that minimises cost and
maximises treatment outcomes in high resource settings [20]. A
cost-effectiveness analysis based on mathematical modelling
assessed multiple HIV monitoring strategies in Southern Africa.
The authors concluded that monitoring RNA-VL and CD4 count
quarterly over twice-yearly has only a modest effect on additional
Figure 3. Multivariable adjusted associations for site resourcing and time to major first-line ART modification. Income group-specific
models are adjusted for age, sex, exposure, HBV, HCV, pre-ART AIDS illness, pre-ART CD4, pre-ART RNA-VL and year of ART initiation.
doi:10.1371/journal.pone.0064902.g003
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life expectancy and contributes to a small reduction in opportu-
nistic diseases [21].
Our study does not report mortality or treatment outcomes
(clinical, immunological and virological) between the different
income groups. Although not directly comparable due to differing
analysis populations, treatment outcome differences in the Asia-
Pacific have been reported elsewhere [22–25]. Briefly, Egger et al
reported a lower absolute mean difference of in mean CD4 cell
counts [247 to 27 cell/mL] in TAHOD compared to AHOD
[23]. A follow-up study by Achhra et al concluded that this mean
CD4 cell count difference translated to minimal clinical signifi-
cance in terms of mortality and new AIDS-defining illness [22]. A
comprehensive analysis of AIDS-related and non-AIDS-related
mortality in AHOD and TAHOD also reported little evidence of
differing hazard ratios of mortality in TAHOD-High and
TAHOD-Low relative to AHOD [24]. However, in a TAHOD-
specific study, Oyomopito et al reported less favorable treatment
outcomes for sites that reported less than once-yearly RNA-VL
testing compared to those sites that monitored RNA-VL at least
once-yearly [25]. In aggregate these finding suggest that there are
minimal population differences in treatment outcomes between
AHOD and TAHOD. Collectively these results are consistent with
a study conducted by the Swiss HIV Cohort Study (SHCS) and
the International Epidemiologic Databases to Evaluate AIDS in
Southern Africa (IeDEA-SA) group that directly compared HIV
treatment outcomes between a high-income country (Switzerland)
and a low-income country (South Africa) [26]. The investigators
concluded that although patients switched treatment much more
often in Switzerland, there were minimal differences between
longer-term treatment outcomes.
Our results are consistent with studies that have previously
evaluated factors associated with switching from first-line ART to
second-line regimens in both resource-rich and resource-limited
settings. Although we cannot compare our results directly due to
differing analysis designs- including reasons for switching algo-
rithms and importantly, regional differences in antiretroviral
treatment guidelines. These studies have found few factors
associated with switching from first-line ART. Of the large
observational cohorts evaluating switching in resource-limited
settings, a large multi-country cohort analysis from the ART-
LINC group showed an increasing risk association between
switching to second-line ART (for any reason) and low pre-ART
CD4 cell count (,150 cells/mL) and earlier time periods of ART
initiation [27]. Similar associations, low pre-ART CD4 and earlier
time-periods of ART initiation were also found in Sub-Saharan
Africa [28].
There are limitations to our analysis. First, although we have
designed an analysis based largely on prospective treatment
records from a population of patients receiving routine care at
multiple sites throughout the Asia-Pacific region, we are unable to
quantify selection bias due to the observational nature of the data.
Second, in our analysis we have used World Bank-defined criteria
to categorise countries into high/middle/low-income groupings
based on gross national income. Clearly, economic prosperity or
disparity change over time, and we note that our income
groupings and the associated results are specific to the observed
time period. Furthermore, we note that the ART treatment
guidelines have changed overtime. Although we have attempted to
address these differences through adjusting for year of ART
initiation, we are unable to quantify any remaining impact on our
result for these treatment guideline changes. Third, our association
analysis endpoint (Table 4, Figure 3) is composite and captures all
major modifications to first-line ART regardless of reason.
Although we have recorded reasons for modification, we are
hesitant to differentiate the analysis (e.g using a competing risk
framework) based on this variable. Reasons for treatment
modification are complex due to co-dependence, where adverse
events influence adherence, which in turn leads to treatment
failure. Furthermore, there are a large number of unreported
reasons for modification in AHOD and exclusion of these events
would likely introduce bias due-to missing information. Finally, we
are unable to evaluate any site-specific bias in the proxy indicator
variable for site resourcing. A given resourcing level (e.g.
2CD4::1RNA-VL) may actually correspond to only a single site
within the income group, thus limiting interpretation of site
resourcing categories with infrequent events or observed person-
years.
In summary, we found that low-income countries tended to
have lower rates of major modifications made to first-line ART
compared to higher income-countries, where increased HIV
monitoring led to increased modifications of first-line ART. The
clinical significance of this finding at an individual patient level is
unknown. Given the current need for life-long therapy in the
management of HIV, further research evaluating the optimal
monitoring schedule which balances overall cost and favorable
treatment outcomes would be of value to both resource-rich and
resource-limited countries.
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